MAP3K5 and Hepatic fibrosis: An open-label phase 2 trial evaluating the investigational ASK1 inhibitor selonsertib (GS-4997) alone or in combination with the monoclonal antibody simtuzumab (SIM) in NASH patients with moderate-to-severe liver fibrosis (stages 2/3).